Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX) had its target price reduced by investment analysts at Deutsche Bank AG from $29.00 to $24.00 in a research note issued on Monday. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price target points to a potential upside of 31.72% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. TD Securities reiterated a “hold” rating and issued a $38.00 price target on shares of Valeant Pharmaceuticals International in a research report on Sunday, July 17th. Mizuho reissued an “underperform” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Wells Fargo & Co. reissued a “sell” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Rodman & Renshaw reissued a “buy” rating and issued a $90.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Finally, Morgan Stanley dropped their price objective on shares of Valeant Pharmaceuticals International from $42.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, November 10th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $39.97.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 18.22 on Monday. The stock’s market capitalization is $6.33 billion. Valeant Pharmaceuticals International has a 12-month low of $13.77 and a 12-month high of $119.87. The firm’s 50-day moving average is $22.04 and its 200 day moving average is $25.21.

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 43.81%. The business earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. During the same quarter last year, the company earned $2.74 EPS. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. Equities analysts expect that Valeant Pharmaceuticals International will post $5.41 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in shares of Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 402 shares during the period. Kistler Tiffany Companies LLC raised its position in shares of Valeant Pharmaceuticals International by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the period. US Bancorp DE raised its position in shares of Valeant Pharmaceuticals International by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the period. Cacti Asset Management LLC raised its position in shares of Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 3,400 shares during the period. Finally, AGF Investments Inc. raised its position in shares of Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock worth $178,000 after buying an additional 4,857 shares during the period. 65.50% of the stock is currently owned by institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.